Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041)
- 주제(키워드) Ovarian cancer , Platinum-resistant , Bevacizumab , Chemotherapy , Real world
- 주제(기타) Oncology; Obstetrics & Gynecology
- 설명문(일반) [Lee, Jung-Yun; Lee, Yong Jae] Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Yonsei Ro 50-1, Seoul 03722, South Korea; [Park, Jeong-Yeol; Kim, Yong-Man] Univ Ulsan, Dept Obstet & Gynecol, Asan Med Ctr, Coll Med, Seoul, South Korea; [Park, Sang Yoon; Kang, Sokbom] Natl Canc Ctr, Ctr Uterine Canc, Goyang, South Korea; [Lee, Jeong-Won] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Kim, Jae Weon] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Kim, Yong Beom] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Obstet & Gynecol, Seongnam, South Korea; [Jeong, Dae Hoon] Inje Univ, Busan Paik Hosp, Paik Inst Clin Res, Busan, South Korea; [Lee, Kwang-Beom] Gachon Univ, Coll Med, Gil Med Ctr, Dept Obstet & Gynecol, Incheon, South Korea; [Kim, Tae-Hun] KIRAMS, Korea Canc Ctr Hosp, Dept Obstet & Gynecol, Seoul, South Korea; [Lee, In Ho] Dankook Univ, Coll Med, Cheil Gen Hosp, Dept Obstet & Gynecol, Seoul, South Korea; [Kim, Tae-Hun] Dankook Univ, Coll Med, Womens Healthcare Ctr, Seoul, South Korea; [Lee, In Ho] CHA Univ, Comprehens Gynecol Canc Ctr, CHA Bundang Med Ctr, Seongnam, South Korea; [Choi, Min Chul] Pusan Natl Univ Hosp, Biomed Res Inst, Sch Med, Dept Obstet & Gynecol, Busan, South Korea; [Kim, Ki Hyung] Univ Paris 05, AH HP, Med Oncol Dept, Paris, France; [Shin, So-Jin] Keimyung Univ, Sch Med, Dept Gynecol & Obstet, Daegu, South Korea; [Hong, Dae Gy] Kyungpook Natl Univ, Dept Obstet & Gynecol, Sch Med, Daegu, South Korea; [Shim, Seung-Hyuk] Konkuk Univ, Sch Med, Dept Obstet & Gynecol, Seoul, South Korea; [Kim, Yun Hwan] Ewha Womans Univ, Coll Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Seoul, South Korea; [Song, Taejong] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Kangbuk Samsung Hosp, Seoul, South Korea; [Bae, Jaeman] Hanyang Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Lee, Jong-Min] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Lee, San Hui] Yonsei Univ, Wonju Coll Med, Dept Obstet & Gynecol, Wonju, South Korea; [Park, Sang-Il] ChungAng Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea; [Park, Sang-Il] DIRAMS Canc Ctr, Dept Gynecol Oncol, Busan, South Korea; [Lee, Sung-Jong] Catholic Univ Korea, Dept Obstet & Gynecol, St Vincents Hosp, Coll Med, Suwon, South Korea; [Lee, Chulmin] Inje Univ, Sanggye Paik Hosp, Dept Obstet & Gynecol, Seoul, South Korea; [Lee, Taek Sang] SMGSNU Boramae Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Chang, Suk-Joon] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Suwon, South Korea; [Kim, Min Kyu] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Changwon Hosp, Chang Won, South Korea
- 후원정보 Korean Soc Gynecol Oncol
- 등재 SCIE, SCOPUS
- 발행기관 ACADEMIC PRESS INC ELSEVIER SCIENCE
- 발행년도 2019
- 회의명 33rd Annual Meeting of the Korean-Society-of-Gynecologic-Oncology
- 개최지 Cheju, SOUTH KOREA
- 일자 27-4월-18
- URI http://www.dcollection.net/handler/ewha/000000160306
- 본문언어 영어
- Published As http://dx.doi.org/10.1016/j.ygyno.2018.10.031
- PubMed https://pubmed.ncbi.nlm.nih.gov/30409490
초록/요약
Purpose. To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum resistant ovarian cancer in a real-world setting. Patients and methods. We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan) between 2015 and 2017 for second- or third-line chemotherapy in routine clinical practice. The primary endpoint was progression-free survival (PFS) and safety. Secondary endpoints included the objective response rate (ORR), PFS2, overall survival, duration of chemotherapy, and reasons for discontinuing chemotherapy. Results. Of 391 patients, 259 (66.2%) received bevacizumab with PLD, 94 (24.0%) with topotecan, and 38 (9.7%) with weekly paclitaxel. The median PFS was 6.1 months with all forms of bevacizumab-containing therapy. Although the cohort with weekly paclitaxel had a better PFS than the PLD cohort (P = 0.028), this finding was not found in patients with a previous platinum-free interval of less than three months. The median duration of therapy was five cycles (range, one to 20 cycles), and 29 patients (7.4%) discontinued treatment because of adverse events from bevacizumab-containing regimens. The PLD cohort had fewer grade >= 3 adverse events than the other regimens (PLD, 35.8%; weekly paclitaxel, 52.6%; topotecan, 51.1%; P = 0.012), especially events of hematologic toxicities. Conclusion. In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study. The effectiveness and toxicity profiles varied among the chemotherapy regimens, and this finding should be considered in practice. (C) 2018 Elsevier Inc. All rights reserved.
more